Advertisement
Advertisement
RAPP
Rapport Therapeutics, Inc. Common Stock
40.45
USDSponsored
-1.50
-3.58%
Sep 18, 15:59 UTC -4
Closed
After-Market
40.48
+0.03
+0.07%
RAPP Earnings Reports
Positive Surprise Ratio
RAPP beat 6 of 9 last estimates.
67%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.24
Implied change from Q2 26 (Revenue/ EPS)
--
/+4.20%
Implied change from Q3 25 (Revenue/ EPS)
--
/+74.65%
Rapport Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, RAPP reported earnings of -1.19 USD per share (EPS) for Q2 26, missing the estimate of -0.97 USD, resulting in a -22.26% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.57% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -1.24 USD, with revenue projected to reach -- USD, implying an increase of 4.20% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Rapport Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Rapport Therapeutics, Inc. Common Stock reported EPS of -$1.19, missing estimates by -22.26%, and revenue of $0.00, 0% as expectations.
How did the market react to Rapport Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.57%, changed from $42.20 before the earnings release to $42.44 the day after.
When is Rapport Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Rapport Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Rapport Therapeutics, Inc. Common Stock is expected to report EPS of -$1.24 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.